Angiopoietins, growth factors, and vascular morphology in early arthritis

Journal of Rheumatology

Volumn 30, Issue 2, 2003, Pages 260-268

  Fearon, Ursula ^a,b   Griosios, Konstantina ^a   Fraser, Alexander ^a   Reece, Richard ^a   Emery, Paul ^a   Jones, Pamela F ^a   Veale, Douglas J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Angiopoietins; Early arthritis; Vascular endothelial growth factor; Vascular morphology

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTHRITIS; ARTHROSCOPY; ARTICLE; CLINICAL ARTICLE; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID LEVEL; SYNOVIUM;

ADULT; AGED; ANGIOGENESIS INDUCING AGENTS; ANGIOPOIETIN-1; ANGIOPOIETIN-2; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; ARTHROSCOPY; ENDOTHELIAL GROWTH FACTORS; HUMANS; IN SITU HYBRIDIZATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; RNA, MESSENGER; SYNOVIAL MEMBRANE; SYNOVITIS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0037309635     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Folkman J, D'Amore PA. Blood vessel formation: what is its molecular basis? Cell 1996;87:1153-5.
2. Polverini PJ. The pathophysiology of angiogenesis. Crit Rev Oral Biol Med 1995;6:230-47.
3. Folkman J. Angiogenesis and angiogenesis inhibition: an overview. EXS 1997;79:1-8.
4. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
5. Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998;91:3527-61.
6. Bicknell R, Harris AL. Novel growth regulatory factors and tumor angiogenesis. Eur J Cancer 1991;27:781-5.
7. Koch AE. Angiogenesis: Implications for rheumatoid arthritis. Arthritis Rheum 1998;41:951-62.
8. Thomas KA. Vascular endothelial growth factor: a potent and selective angiogenic agent. J Biol Chem 1996;271:603-6.
9. Clauss M, Gerlach M, Gerlach H. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990;172:1535-45.
10. Reuterdah C, Tingstrom A, Terracio L, Keiko F, Heldin CH, Rubin K. Characterization of platelet-derived growth factor-β receptor expressing cells in the vasculature of human rheumatoid synovium. J Clin Invest 1991;64:321-9.
11. Feldman M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
12. Goddard DH, Grossman SL, Williams WV, et al. Regulation of synovial cell growth: coexpression of transforming growth factor B and basic fibroblast growth factor by cultured synovial cells. Arthritis Rheum 1992;35:1296-303.
13. Koch AE, Polverini PJ, Kundel SL. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992;258:1798-801.
14. Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 1996;87:3877-82.
15. Dumont DJ, Fong GH, Puri MC, Gradwohl G, Alitalo K, Breitman ML. Vascularization of the mouse embryo: a study of fik-1, tek, tie, and vascular endothelial growth factor expression during development. Dev Dyn 1995;203:80-92.
16. Sato TN, Tozawa Y, Deutsch U, et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995;376:70-4.
17. Davis S, Gale NW, Aldrich TH, et al. Isolation of angiopoietin-1, a ligand for the Tie-2 receptor, by secretion-trap expression cloning. Cell 1996;87:1161-9.
18. Suri C, Jones P, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the Tie-2 receptor, during embryonic angiogenesis. Cell 1996;87:1170-80.
19. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin 2, a natural antagonist for Tie 2 that disrupts angiogenesis. Science 1997;277:55-8.
20. Tunn EJ, Bacon PA. Differentiating persistent from self-limiting symmetrical synovitis in an early arthritis clinic. Br J Rheumatol 1993;32:97-103.
21. Espinoza LR, Vasey FB, Espinoza CG, Bocanegra TS, Germain BF. Vascular changes in psoriatic synovium. Arthritis Rheum 1982;25:677-84.
22. Veale D, Yanni G, Rogers S, Bames L, Bresnihan B, FitzGerald O. Reduced synovial macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis compared to rheumatoid arthritis. Arthritis Rheum 1993;36:893-900.
23. Reece R, Canete J, Parsons W, Emery P, Veale DJ. Distinct vascular patterns in the synovitis of psoriatic, reactive and rheumatoid arthritis. Arthritis Rheum 1999;42:1481-5.
24. Costello P, Winchester RJ, Curran SA, et al. Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen driven. J Immunol 2001;166:2878-86.
25. Colville-Nash P, Scott DL. Angiogenesis and rheumatoid arthritis: Pathogenic and therapeutic implications. Ann Rheum Dis 1992;51:919-25.
26. Chu CQ, Field M, Abney E, Zheng RQH, Allard S, Feldman M. Transforming growth factor-β in rheumatoid synovial membrane and cartilage/pannus junction. Clin Exp Immunol 1991;86:380-6.
27. Bottomley MJ, Webb NJ, Watson CJ, Holt PJ, Freemont AJ, Brenchley P. Peripheral blood mononuclear cells from patients with rheumatoid arthritis spontaneously secrete vascular endothelial growth factor: specific upregulation by tumor necrosis factor-α in synovial fluid. Clin Exp Immunol 1999;117:171-6.
28. Koch AS, Harlow LA, Haines GK, et al. Vascular endothelial growth factor: a cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994;152:4149-56.
29. Fava R, Olsen N, Spencer-Green G. et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994;180:341-6.
30. Paleolog EM, Young S, Stark AC, McCloskey RV, Feldman M, Maini RN. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 1998;41:1258-65.
31. Braverman IM, Yen A. Microcirculation in psoriatic skin. J Invest Dermatol 1974;62:493-502.
32. Braverman IM, Yen A. Ultrastructure of the capillary loops in the dermal papillae of psoriasis. J Invest Dermatol 1977;68:53-60.
33. Hull S, Goodfield M, Wood EJ, Cunliffe WJ. Active and inactive edges of psoriatic plaques: Identification by tracing and investigation by laser-doppler flowmetry and immunocytochemical techniques. J Invest Dermatol 1989;92:782-5.
34. Veale D, Barnes L, Rogers S. FitzGerald O. Immunolocalisation of adhesion molecules in psoriatic arthritis, psoriatic and normal skin. Br J Dermatol 1995;132:32-8.
35. Griffiths CEM, Voorhees JJ, Nickoloff BJ. Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor. J Am Acad Dermatol 1989;20:617-29.
36. Creamer D, Jaggar R, Allen M, Bicknell R, Barker J. Overexpression of the angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase in psoriatic epidermis. Br J Dermatol 1997;137:851-5.
37. Zaric D, Worm AM. Stahl D, Clemmensen OJ. Capillary microscopy of the nailfold in psoriatic and rheumatoid arthritis. Scand J Rheumatol 1981;10:249-52.
38. Sano H, Forough R, Maier JA, et al. Detection of high levels of heparin binding growth factor 1 (acidic fibroblast growth factor) in inflammatory arthritic groups. J Cell Biol 1990;110:1417-22.
39. Byrd V, Zhao X-M, McKeehan WL, Miller GG, Thomas JW. Expression and functional expansion of fibroblast growth factor receptor T cells in rheumatoid arthritis. Arthritis Rheum 1996; 39:914-22.
40. Sano H, Engleka K, Mathern P, et al. Co-expression of phosphotyrosine-containing proteins, platelet-derived growth factor-β, and fibroblast growth factor-1 in situ in synovial tissues of patients with rheumatoid arthritis and Lewis rats with adjuvant or streptococcal cell wall arthritis. J Clin Invest 1993;91:553-65.
41. Asahara T, Chen D, Takahashi T, et al. Tie 2 receptor ligands, angiopoietin 1 and angiopoietin 2, modulate VEGF-induced postnatal neovascularization. Circ Res 1998;83:233-40.
42. Suri C, McClain J, Thruston G, et al. Increased vascularisation in mice overexpressing angiopoietin-1. Science 1998;282:468-71.
43. Zagzag D, Hooper A, Friedlander DR, et al. In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp Neurol 1999;159:391-400.
44. Holash J, Maisonpierre BC, Compton D, et al. Vessel cooption, regression and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994-8.
45. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
46. Veale DJ. The role of arthroscopy in early arthritis. Clin Exp Rheumatol 1999;17:37-8.
47. Youssef PP, Kraan M, Breedveld F, et al. Quantitative analysis of inflammation in rheumatoid arthritis synovial membrane samples selected at arthroscopy compared with samples obtained blindly by needle biopsy. Arthritis Rheum 1998;41:663-9.
48. Veale DJ, Reece RJ, Orgles CS, et al. Intra-articular therapy with anti-CD-4 monoclonal antibody in RA: A magnetic resonance and arthroscopic study. Ann Rheum Dis 1999;58:342-9.
49. Tak PP, van der Lubbe PA, Caulie A, et al. Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum 1995;38:1457-65.
50. Youssef PP, Smeet TJ, Bresnihan B, et al. Microscopic measurement of cellular infiltration in the rheumatoid arthritis synovial membrane: a comparison of semi-quantitative and quantitative analysis. Br J Rheumatol 1998;37:1003-7.
51. Cunnane G, Fitzgerald O, Hummel KM, Gay RE, Gay S, Bresnihan B. Collagenase, cathepsin B and cathespin L gene expression in the synovial membrane of patients with early inflammatory arthritis. Rheumatology 1999;38:32-42.
52. Fearon U, Reece RJ, Blythe D, Jack A, Emery P, Veale DJ. Synovial cytokine and growth factor regulation of MMPs/TIMPs: implications for erosions and angiogenesis in early rheumatoid and psoriatic arthritis patients. Ann NY Acad Sci 1999;78:619-21.
53. Fraser A, Fearon U, Reece R, Emery P, Veale DJ. Matrix metalloproteinase 9, apoptosis, and vascular morphology in early arthritis. Arthritis Rheum 2001;44:2024-8.
54. Veale D, FitzGerald O. Clinical and immunohistological features in psoriatic arthritis. J Ir Coll Phys Surg 1993;22:212-6.
55. Revell PA, Mayston V. Histopathology of the synovial membrane of peripheral joints in ankylosing spondylitis. Ann Rheum Dis 1982;41:579-86.
56. Jones SM, Dixey J, Hall ND, McHugh NJ. Expression of the cutaneous lymphocyte antigen and its counter-receptor E-selectin in the skin and joints of patients with psoriatic arthritis. Br J Rheumatol 1997;36:748-57.
57. Mulherin D, Veale DJ, Belch JJF, Bresnihan B, FitzGerald O. Adhesion molecule levels in previously untreated inflammatory arthritis. QJM 1996;89:195-203.
58. FitzGerald O, Soden M, Yanni G. Robinson R, Bresnihan B. Morphometric analysis of blood vessels in synovial membranes obtained from clinically affected and unaffected knee joints of patients with rheumatoid arthritis. Ann Rheum Dis 1991;50:792-6.
59. Blake DR, Merry P, Unsworth J, et al. Hypoxic-reperfusion injury in the inflamed human joint. Lancet 1989;2:289-93.
60. Blake DR, Winyard PG, Marok R. The contribution of hypoxicreperfusion injury to inflammatory synovitis: the influence of reactive oxygen intermediates on the transcriptional control of inflammation. Ann NY Acad Sci 1994;723:308-17.
61. Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or chronic hypoxia. J Clin Invest 1995;95:1798-807.
62. Fava RA, Olsen NJ, Postlewaite AE, et al. Transforming growth factor β1 (TGFβ1) induced neutrophil recruitment to synovial tissues: implications for TGFβ1 driven synovial inflammation. J Exp Med 1991;173:1121-32.
63. DeVries C, Escobedo JA, Veno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992;255:989-91.
64. Breier G, Clauss M, Risau W. Coordinate expression of vascular endothelial growth factor receptor-1 (flt-1) and its ligand suggests a paracrine regulation of murine vascular development. Dev Dyn 1995;204:228-39.
65. Barleon B, Hauser S, Schollman C, et al. Differential expression of the two VEGF receptors flt and KDR in placenta and vascular endothelial cells. J Cell Biochem 1994;54:56-66.
66. Ranicke V, Risau W, Breier C. Characterisation of the endothelium-specific murine vascular growth factor receptor-2 (flk-1) promotor. Circ Res 1996;79:277-85.
67. Ikeda M, Hosoda Y, Hirose S, Okada Y, Ikeda E. Expression of vascular endothelial growth factor isoforms and their receptors Flt-1, KDR, and neuropilin-I in synovial tissues of rheumatoid arthritis. J Pathol 2000;191:426-33.
68. Vikkula M, Boon LM, Carraway KL III, et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 1996;87:1181-90.
69. Scott BB, Zaratin PF, Colombo A, Hansbury MJ, Winkler JD, Jackson JR. Constitutive expression of angiopoietin 1 and 2 and modulation of their expression by inflammatory cytokines in rheumatoid arthritis synovial fibroblasts. J Rheumatol 2002;29:230-9.
70. Peters KG. Vascular endothelial growth factor and the angiopoietins. Working together to build a better blood vessel. Circ Res 1998;83:342-3.